Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.